How much does Encidipine cost? Is it covered by medical insurance?

Enasidenib (IDHIFA, Enasidenib) is a targeted therapy for patients with acute myeloid leukemia (AML), specifically those who carry mutations in the isocitrate dehydrogenase 2 (IDH2) gene. Ensidipine is a small molecule drug that can be administered orally. It binds highly selectively to the active site of the mutated IDH2 enzyme and acts by inhibiting its catalytic activity.

Ensidipine is a small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2). Ensidipine targets mutant IDH2 variants R140Q, R172S, and R172K in vitro at approximately 40-fold lower concentrations than the wild-type enzyme. In a mouse xenograft model of IDH2 mutant AML, ensidipineinhibition of the mutant IDH2 enzyme resulted in reduced 2-hydroxyglutarate (2-HG) levels and induction of myeloid differentiation in vitro and in vivo. In blood samples from IDH2-mutated AML patients,ensidipine reduce 2-HG levels, reduce blast counts, and increase the percentage of mature myeloid cells.

in the country, ensidipine is not currently on the market, so it cannot be reimbursed by medical insurance.对于需求此药的患者来说，他们需要从海外购买或咨询专业的海外医疗咨询公司。 As far as we know, generic drugs of ensidipine have been sold overseas, including versions produced by Bangladesh's Ziska Pharmaceutical and Laos' Lucius Pharmaceutical, and the price is about more than a box (30 tablets) of more than . For more information about ensidipine, please consult a professional overseas medical consulting company.

In general, ensidipine provides a new treatment strategy for AML patients with IDH2 mutations. Its unique targeting and significant clinical effects bring hope to these patients. However, it is also necessary to pay close attention to the patient's response during use to ensure the safety and effectiveness of the treatment.